Rchr
J-GLOBAL ID：202201012392317618   Update date: Aug. 20, 2024

Anraku tsutomu

アンラク ツトム | Anraku tsutomu
Affiliation and department：
Niigata University

About Niigata University


Papers (10)：
  • Tsutomu Anraku, Masaki Murata, Hiroo Kuroki, Akira Kazama, Yuko Shirono, Masayuki Tasaki, Vladimir Bilim, Yoshihiko Tomita. Selective HDAC6 Inhibition Has the Potential for Anti-Cancer Effect in Renal Cell Carcinoma. Journal of personalized medicine. 2024. 14. 7
  • Yuko Shirono, Vladimir Bilim, Tsutomu Anraku, Hiroo Kuroki, Akira Kazama, Masaki Murata, Kaede Hiruma, Yoshihiko Tomita. Targeting Pro-Survival Autophagy Enhanced GSK-3β Inhibition-Induced Apoptosis and Retarded Proliferation in Bladder Cancer Cells. Current oncology (Toronto, Ont.). 2023. 30. 6. 5350-5365
  • Tsutomu Anraku, Hideki Hashidate, Asa Nakahara, Tomoyuki Imai, Yoshiaki Kawakami. Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy. BMC urology. 2023. 23. 1. 38-38
  • Akira Kazama, Vladimir Bilim, Masayuki Tasaki, Tsutomu Anraku, Hiroo Kuroki, Yuko Shirono, Masaki Murata, Kaede Hiruma, Yoshihiko Tomita. Tumor-infiltrating immune cell status predicts successful response to immune checkpoint inhibitors in renal cell carcinoma. Scientific reports. 2022. 12. 1. 20386-20386
  • Tsutomu Anraku, Hideki Hashidate, Asa Nakahara, Tomoyuki Imai, Yoshiaki Kawakami. A 40-year-old man with a rapidly growing intrascrotal tumor in the fibroma-thecoma group. IJU case reports. 2022. 5. 3. 175-178
ｍore...
MISC (3)：
Professional career (1)：
  • MD (Niigata University)
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM